Ginkgo Bioworks Holdings

$8.94
(as of Jun 13, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Ginkgo Bioworks Holdings

Stock Price
$8.94
Ticker Symbol
DNA
Exchange
NYSE

Industry Information for Ginkgo Bioworks Holdings

Sector
Healthcare
Industry
Biotechnology

Company Description for Ginkgo Bioworks Holdings

Country
USA
Full Time Employees
834

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. The company serves the pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Fundamentals for Ginkgo Bioworks Holdings

Market Capitalization
$572,441,984
EBITDA
$-325,196,992
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-10.25
Earnings per Share Estimate Next Year
Profit Margin
-198.84%
Shares Outstanding
46,344,600
Percent Owned by Insiders
6.69%
Percent Owned by Institutions
79.41%
52-Week High
52-Week Low

Technical Indicators for Ginkgo Bioworks Holdings

50-Day Moving Average
200-Day Moving Average
RSI
60.22
0.65

Analyst Ratings for Ginkgo Bioworks Holdings

Strong Buy
1
Buy
0
Hold
1
Sell
3
Strong Sell
1

News About Ginkgo Bioworks Holdings

May 8, 2025, 8:00 AM EST
New terms provide Twist with key license to long DNA technology and assets See more.
Apr 22, 2025, 9:00 AM EST
BOSTON, April 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a Reconfigurable Automation Cart (RAC) system to Aura Genetics, a high-complexity diagnostic laboratory servicing the growing at-home testing and wellness market. See more.
Apr 10, 2025, 9:55 AM EST
Shares of Ginkgo Bioworks Holdings, Inc. See more.
Apr 10, 2025, 9:00 AM EST
Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems See more.